AbCellera Biologics Inc. — Director's Dealing 2020

Dec 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbCellera Biologics Inc. (ABCL)
CIK: 0001703057
Period of Report: 2020-12-15

Reporting Person: Stimart Tryn (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-15	Common Shares	P	250	$20.00	Acquired	250	Direct
2020-12-15	Common Shares	P	250	$20.00	Acquired	250	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-29	Stock Option (right to buy)	$2.41	A	850000	Acquired	2030-10-29	Common Shares (850000)	Direct
2020-12-10	Stock Option (right to buy)	$20.00	A	190800	Acquired	2030-12-10	Common Shares (190800)	Direct

Footnotes

F1: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F2: The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00.

F3: 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F4: 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F5: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.